Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $169

Benzinga · 6d ago
Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $162 to $169.